Hydroxymethyglutaryl coenzyme A reductase inhibition (statin) therapy has been shown to reduce cardiac hypertrophy in vitro and in vivo. We assessed the influence of short-term statin therapy on left ventricular (LV) remodeling after acute myocardial infarction. Thirty-five patients with first anterior acute myocardial infarction, who underwent primary coronary angioplasty within 12 hours of onset, were divided into 2 groups. Ten patients taking statin served as the statin group, and 25 patients not taking statin served as the control group. Two-dimensional echocardiography was recorded after angioplasty (baseline) and at 4 weeks. LV ejection fraction (LVEF) at baseline was not significantly different between the 2 groups. However, the statin group had a higher LVEF at 4 weeks than the control group (58.2 ± 5.0 versus 49.0 ± 12.7%; P < 0.05). Moreover, the increase in LV end-diastolic volume (LVEDV) at 4 weeks was lower in the statin group than in the control group (12.1 ± 29.6 versus 39.9 ± 35.7 mL; P < 0.05). Multiple regression analysis demonstrated that administration of statin was an independent factor for the increase in LVEDV (P < 0.05). These findings indicate that short-term statin therapy can prevent postinfarct LV remodeling and improve LV function. (Int Heart J 2005; 46: 987-995) 
after AMI.
3) Similarly, a β-adrenergic receptor antagonist reduced LV volume, and increased LV ejection fraction. 4) On the other hand, hydroxymethylglutaryl coenzyme A reductase inhibition (statin) therapy has been shown to improve endothelial function 5) and suppress systemic inflammatory responses in patients with coronary artery disease and hyperlipidemia. Moreover, it has been reported that statin therapy has effects beyond lipid lowering, and treatment after AMI may be beneficial not merely for secondary prevention of repeat infarction. [7] [8] [9] Proposed beneficial actions include antioxidant 7) and anti-inflammatory effects, 10) upregulation of endothelial nitric oxide synthase (eNOS), 8, 11) reversal of endothelial dysfunction, 9, 12) and induction of angiogenesis. 13) However, little has been reported on whether statin therapy improves LV function and prevents LV remodeling in patients with AMI. In this study, we assessed the influence of statin therapy on LV remodeling and LV function after AMI.
METHODS

Study population:
The study population consisted of 39 consecutive patients who experienced their first anterior AMI and had undergone primary coronary angioplasty within 12 hours of the onset of AMI between April 2002 and January 2004. A diagnosis of AMI was defined as (1) chest pain continuing for more than 30 minutes, (2) ST elevation > 2.0 mm in ≥ 2 contiguous electrocardiographic leads, (3) an increase in serum creatine phosphokinase > 3 fold over normal values, and (4) TIMI grade 0, 1, or 2 flow at the time of the initial coronary angioplasty. Patients with previous myocardial infarction, primary myocardial disease, renal failure (serum creatine > 2.0 mg/dL), or cardiac shock were excluded from study. The remaining 35 patients were enrolled. Informed consent for primary coronary angioplasty was obtained from all patients and/or their families before the procedure. Study design and protocol: Coronary angiography was performed using the standard femoral approach by Judkin's technique. All patients were administered an intravenous injection of heparin (5000 U) and nitroglycerin (0.3 mg) before coronary angiography. After an additional intravenous or intra-arterial bolus injection of heparin (5000 U), all patients underwent initial balloon angioplasty followed by coronary stenting. The end point of the coronary angioplasty procedure was defined as a residual stenosis < 25%, based on visual assessment. After the procedure, heparin was infused intravenously at 500 U/h. All patients were treated with oral aspirin (162 mg/day) and ticlopidine (200 mg/day) for 1 month after the procedure, followed by aspirin alone (81 mg/day). No patient was treated with glycoprotein IIb/IIIa inhibitors. The present study was designed as a single-center study to assess the influence of statin therapy on LV remodeling and LV function after AMI. Patients received statin therapy or standard care (lipid-lowering diet). The treatment was determined by the primary physician, who did not know the results of coronary angioplasty. Thirty-five patients were divided into two groups, statin (n = 10) and nonstatin (n = 25). Nine patients in the statin group had hypercholesterolemia (fasting serum total cholesterol > 220 mg/dL) and 21 patients in the nonstatin group had hypercholesterolemia. Starting on day 1, drug was administered to the statin group (atorvastatin to 7 patients, pravastatin to 3 patients). Both atorvastatin and pravastatin were administered at a dose of 10 mg daily. ACE inhibitor (quinapril) administration was started at a dose of 5 mg daily to all patients 1 day after the onset. If required, oral nitrates, calcium antagonists, β-blockers, or diuretics were added and continued. No patient was treated with an angiotensin II receptor blocker.
Transthoracic echocardiography was performed within 24 hours of coronary angioplasty (SONOS 5500, Philips, Andover, MA, USA). Images were recorded on optical disks. LV end-diastolic volume (LVEDV) and ejection fraction (EF) were determined from apical 2-chamber and 4-chamber views, directly after coronary angioplasty and after 4 weeks, using the modified Simpson's method. All tracings of endocardial borders were performed manually 3 times and the measurements were averaged. An increase in LVEDV at 4 weeks was defined as LV remodeling (> 20% increase from baseline).
14)
The left ventricle was divided into 16 segments as previously described. 15) For each segment, systolic wall motion and thickening were visually graded using the following semiquantitative scoring system: normal, 0; hypokinesis, 1; severe hypokinesis, 2; akinesis, 3; and dyskinesis, 4. Seven of the 16 segments were determined to be in the vicinity of the left anterior descending coronary artery (LAD), and the anterior wall motion score index (A-WMSI) was calculated as an average of the wall motion scores in 7 segments. Statistical analysis: Data are expressed as the mean ± SD. Comparisons between 2 groups were performed using Student's t test for continuous variables, or the chi-square test for categorical variables. Comparison between the two groups at each time was performed using an unpaired t test. Comparisons within groups at each point were performed using a paired t test. Multiple regression analysis was performed to determine the independent predictors for the increase in LVEVD at 4 weeks. For all analyses, a P value < 0.05 was considered significant.
RESULTS
Clinical characteristics:
The clinical characteristics are shown in Table I . There were no differences in age, gender, diabetes mellitus, hypertension, smoking, onset to reflow time, peak CPK, or concurrent medications between the 2 groups. The statin group had slightly higher levels of serum total cholesterol and LDL cholesterol than the nonstatin group. LV volume and function: LVEF, LVEDV, LVESV, and A-WMSI at baseline were not significantly different between the 2 groups. The statin group had a significantly higher LVEF at 4 weeks than the nonstatin group (58.2 ± 5.0 versus 49.0 ± 12.7%, P < 0.05). LVEF was significantly increased at 4 weeks in the statin group (statin group, P < 0.0001; nonstatin group, P = NS). LVEDV was significantly increased at 4 weeks in the nonstatin group (nonstatin group, P < 0.0001; statin group, P = NS). Similarly, LVESV was significantly increased at 4 weeks in the nonstatin group (nonstatin group, P < 0.0005; statin group, P = NS) (Figure , Table II ). In the statin group, the increase in LVEDV at 4 weeks was significantly reduced compared to that in the nonstatin group (12.1 ± 29.6 versus 39.9 ± 35.7 mL, P < 0.05) (Table II) . Independent predictors of LV remodeling: Multivariate analysis was performed to determine the increase in LVEDV. The variables included age, sex, coronary risk factors, peak CPK, onset to reflow time, diuretics, calcium antagonists, and statins. According to multiple regression analysis, the absence of statin administration and female sex were significant independent predictors of an enlargement of LVEDV 4 weeks after the onset (Table III) .
DISCUSSION
The findings of the present study demonstrate that short-term combination therapy with a statin plus an ACE inhibitor, started at the onset of AMI immediately after coronary angioplasty, can prevent LV enlargement and improve LVEF in patients with a first anterior AMI, compared with treatment with an ACE inhibitor alone.
The process of LV enlargement after AMI involves architectural rearrangement both in the infarcted and in the surrounding noninfarcted myocardium over the days after the acute ischemic event. The exact mechanisms that govern LV enlargement are still incompletely understood. ACE inhibitors and β-blockers attenuate ventricular enlargement in patients after AMI. Lefer, et al 16) have shown that myocardial ischemia-reperfusion injury can be prevented by statins. However, it has not been shown whether statin therapy affects postinfarct conditions. The present study extends the previous findings that statins can inhibit not only ischemia-reperfusion injury, but also LV enlargement and dysfunction.
Several possible mechanisms explain the beneficial effects of statins on LV structure and function. First, we hypothesized that statins might exert an inhibitory effect on matrix metalloproteinases (MMPs), leading to the prevention of LV enlargement and dysfunction. MMPs play an important role in the degeneration of extracellular matrix, 17) increases in MMP activity and expression are concurrent with a reduction in total myocardial content, LV enlargement, and myocardial contractile dysfunction. 18) Previous studies have demonstrated that expression of MMPs was enhanced during the progression of LV dilatation in animal heart failure models, 19, 20) and that MMP inhibitors limited the chamber dilatation in a murine model of MI. 21) Soejima, et al 22) demonstrated that high levels of expression and activity of MMPs in the acute phase after AMI predict advanced LV remodeling. In the present study, statins, in the same way as MMP inhibitors, might have suppressed the increase in LVEDV and improved LVEF at 4 weeks post AMI. In addition, a transient increase in activity of MMPs in the LV began 2 days after MI, peaked at day 7, and declined thereafter. 23) This suggests that statin therapy started immediately after onset is associated with suppression Vol 46 No 6 of MMP activity and plays a significant role in preventing postinfarction LV remodeling. Furthermore, ACE inhibitors also suppressed the expression of MMPs and prevented LV enlargement. 24) Therefore, these results indicate that combination therapy with a statin and an ACE inhibitor is more effective at preventing LV enlargement than an ACE inhibitor alone.
We similarly hypothesized that statins reduce inflammatory cytokine levels, following their production by activated macrophages, the vascular cell wall, and cardiac myocytes. 25, 26) Inflammatory cytokines and C-reactive protein are elevated during the process of LV remodeling, in particular tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), which induce apoptosis in cardiac myocytes.
27,28) Although we could not clarify the mechanism by which statins reduce inflammatory cytokine levels, it is possible that statins improve LV function in patients with AMI by exerting inhibitory effects on inflammatory cytokines.
Second, the beneficial effects of statins on LV enlargement after MI may be mediated by an attenuation of endothelin-1 synthesis. 29) In particular, inhibition of Rho geranylgeranylation leads to increased endothelial NO production 8) and decreased endothelin-1 expression, 29) factors that are favorable for improvement of endothelial function. As a result, this benefit of improving endothelial function may also induce improved LV function. Study limitations: First, the number of patients included in this study was relatively small and was limited to patients with anterior AMI. Therefore, the results of this study have not been established in patients with inferior or posterior AMI. Second, follow-up echocardiography was not performed in all patients. Therefore, LVEDV was not assessed in chronic terms. In addition, it was unclear whether long-term statin therapy improved LV function and cardiac events after AMI in this study. We did not demonstrate the effects of statin on patient longterm clinical outcomes. Third, we did not measure serum MMP concentrations, proinflammatory cytokine levels, or high sensitivity C-reactive protein. Therefore, there were no convincing data available in this study. Finally, not all patients in the study were taking the same statin. Moreover, we did not address possible differences in the effects of atorvastatin and pravastatin on LV function, because of the small number of patients.
Conclusions:
The results of the present study demonstrate that short-term combination therapy with a statin and an ACE inhibitor can prevent LV remodeling and improve LVEF in patients with a first anterior AMI compared with an ACE inhibitor alone. We hope that our findings will pave the way for additional large-scale clinical trials to evaluate the benefits of statins in patients with AMI.
